June 23, 2021 By Grow Opportunity staff
Cannabis concentrates producer, MediPharm Labs Corp. has entered into a research agreement with McMaster University to support three clinic trials to develop cannabis-based drugs.
Under the agreement, MediPharm will use its cannabis drug licence to provide material, as well as investigative protocol and regulatory approval support. The trials will evaluate the effectiveness of proprietary THC and CBD drug candidates for different indications including, pain, insomnia associated with major depression and uremic pruritus.
“We are honoured to partner with McMaster University, a global leader in medical cannabis research,” said Keith Strachan, President and Interim CEO of MediPharm Labs. “This will further our initiative to fulfill the global need for pharmaceutically approved drugs containing cannabis.”
Print this page
- Former CannTrust executives face securities charges
- Cheaper, more potent cannabis found in B.C. government-run stores: study